Secondary cancers following CAR T cell therap

<p><strong>PHILADELPHIA &ndash; </strong>The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in <a href="https://www.nature.com/articles/s41591-024-02826-w"><em>Nature Medicine</em></a>. The team also described a single case of an incidental T cell lymphoma that did not express the CAR gene and was found in the lymph node of a patient who developed a secondary lung tumor following CAR T cell therapy.</p>

Related Keywords

Pennsylvania ,United States ,Philadelphia ,Princeton ,University Of Pennsylvania ,Chester County ,Pennsylvania Hospital ,New Jersey ,Jodi Fisher Horowitz ,Marco Ruella ,David Porter ,Penn Medicine Princeton Health ,University Of Pennsylvania Health System ,Lancaster Behavioral Health Hospital ,Lymphoma Program ,Abramson Cancer Center ,Perelman School Of Medicine ,National Institutes Of Health ,Princeton House Behavioral Health ,Penn Presbyterian Medical Center ,Hospital Of The University Pennsylvania ,Ruth Perelman School Of Medicine ,Penn Medicine ,Perelman School ,Scientific Director ,Penn Medicine Cellular Therapy ,Transplant Biobank ,Leukemia Care Excellence ,Cell Therapy ,Abramson Cancer ,Pennsylvania Health System ,Ruth Perelman School ,National Institutes ,Susquehanna River ,Chester County Hospital ,Lancaster General Health ,Good Shepherd Penn Partners ,